[Translation] An open-label, multicenter, phase Ia/Ib study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TSN084 tablets in patients with advanced malignant tumors
主要研究目的:评估TSN084片在晚期或转移性恶性肿瘤受试者中的安全性、耐受性、剂量限制性毒性(DLTs)和初步抗肿瘤活性,确定最大耐受剂量(MTD)、扩展期推荐剂量(RDE)和II期临床研究推荐剂量。次要研究目的:评估TSN084片药代动力学(PK)特征和初步抗肿瘤活性。探索性研究目的:探索TSN084的暴露量/剂量与安全性以及临床疗效之间的关系以及生物标志物。
[Translation] Main research objectives: To evaluate the safety, tolerability, dose-limiting toxicities (DLTs) and preliminary anti-tumor activity of TSN084 tablets in subjects with advanced or metastatic malignancies, to determine the maximum tolerated dose (MTD), the extension period Recommended dose (RDE) and recommended dose for Phase II clinical studies. Secondary study objectives: To evaluate the pharmacokinetic (PK) characteristics and preliminary antitumor activity of TSN084 tablets. Exploratory study purpose: To explore the relationship between TSN084 exposure/dose and safety and clinical efficacy and biomarkers.